The Barcelona-based biotech will use the financing to complete a 30-patient Phase 2a study of its lead candidate CTH120, with the first efficacy data expected in mid-2027.
Tag Archive for: startups
Spanish biotech Vaxdyn has raised an €11 million Series A to take K-VAX, its vaccine against Klebsiella pneumoniae and Acinetobacter baumannii, into a first-in-human Phase 1 trial. Portuguese investor Biovance Capital led the round with a €4 million investment, joined by the European Innovation Council (EIC) Fund and the Impacto Andalusia fund managed by Arcano Partners.
Copenhagen’s BioInnovation Institute (BII) is providing six early-stage companies with €1.3 million each in convertible loans, taking its total financing of each startup to €1.8 million.
Dutch startup Revealis Biotherapeutics has launched to develop a new generation of cancer vaccines targeting tumor cells that have become difficult for T cells to recognize, building on an academic program that has already reached patients.
Heidelberg-based Revier Therapeutics has raised €6 million in seed financing to develop selective class IIa histone deacetylase (HDAC) inhibitors for cardiometabolic diseases.
Newly formed Synaptiq Therapeutics has acquired substantially all the assets of Nobias Therapeutics, including a clinical-stage drug whose development has already spanned several companies and more than three decades.
Swiss biotech Immitra Bio has raised CHF 2.4 million (€2.6 million) in pre-seed funding to advance an in-vivo gene editing platform initially targeting inherited blood disorders.
French biotech Brenus Pharma has raised an €11 million Series A extension to complete the Phase 1 development of its lead colorectal cancer immunotherapy and advance a second programme from its platform.
Belgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis.
Kelli McClintock auf UnsplashTen young European biotechs are heading into 2026 with the kind of momentum that can quickly turn promising science into defining data: first clinical entries, platform-to-pipeline transitions, and funding rounds large enough to accelerate execution. Some are pushing new modalities into hard disease areas, while others are compressing discovery timelines and expanding what’s druggable. What they all share is a clear momentum that makes them especially worth following this year.